

Resource Summary Report

Generated by [RRID](#) on Aug 27, 2026

FU-OV-1

RRID:CVCL_2047

Type: Cell Line

Proper Citation

RRID:CVCL_2047

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2047

Proper Citation: RRID:CVCL_2047

Description: Cell line FU-OV-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: High grade ovarian serous adenocarcinoma

Defining Citation: [PMID:10337661](#), [PMID:22460905](#), [PMID:22710073](#), [PMID:23415752](#), [PMID:23839242](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30485824](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: FU-OV-1

Synonyms: FUOV-1, FUOV1, Fukuoka University-OVarian-1

Cross References: CLO:CLO_0003406, EFO:EFO_0022689, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN03471610, BioSample:SAMN10988241, cancercellines:CVCL_2047, Cell_Model_Passport:SIDM01040, Cosmic:1305328, Cosmic:1995408, Cosmic-CLP:1240129, DepMap:ACH-000574, DSMZ:ACC-444, DSMZCellDive:ACC-444, EGA:EGAS00001000978, GDSC:1240129, GEO:GSM274702, GEO:GSM645842,

GEO:GSM711719, GEO:GSM851917, GEO:GSM887014, GEO:GSM888083, GEO:GSM1669796, IARC_TP53:28353, LiGeA:CCLE_783, LINCS_LDP:LCL-1695, Pharmacodb:FUOV1_370_2019, PRIDE:PXD030304, Progenetix:CVCL_2047, Wikidata:Q54835245

ID: CVCL_2047

Record Creation Time: 20220427T215855+0000

Record Last Update: 20260815T232825+0000

Ratings and Alerts

No rating or validation information has been found for FU-OV-1.

No alerts have been found for FU-OV-1.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Zeng Z, et al. (2026) Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer. British journal of cancer, 134(12), 1830.

Jorgensen A, et al. (2026) Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance. Advanced biology, 10(3), e00404.

Kwiatkowski N, et al. (2025) CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers. Cell chemical biology, 32(4), 556.

Xu H, et al. (2024) CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer. iScience, 27(7), 109978.

Dietrich C, et al. (2024) INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors. Cancer discovery, 14(3), 446.

Xu H, et al. (2021) CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. Cell reports. Medicine, 2(9), 100394.